2 weeks Ago By ABMN Staff
Corebridge Financial Inc. boosted its position in Xencor, Inc. ( NASDAQ:XNCR – Free Report ) by 5.
1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,946 shares of the biopharmaceutical company’s stock after buying an additional 1,743 shares during the period. Corebridge Financial Inc.
’s holdings in Xencor were worth $826,000 at the end of the most recent quarter. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc.
raised its position in shares of Xencor by 5.5% during the fourth quarter. Vanguard Group Inc.
now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after purchasing an additional 418,040 shares during the period. Raymond James Financial Inc. acquired a new position in Xencor during the fourth quarter worth $2,329,000.
Barclays PLC raised its holdings in Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after buying an additional 78,066 shares during the last quarter.
Principal Financial Group Inc. lifted its stake in shares of Xencor by 16.5% in the fourth quarter.
Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company’s stock valued at $7,817,000 after buying an additional 48,229 shares in the last quarter. Finally, Charles Schwab Investment Management Inc.
grew its holdings in shares of Xencor by 7.0% during the third quarter. Charles Schwab Investment Management Inc.
now owns 626,988 shares of the biopharmaceutical company’s stock valued at $12,609,000 after buying an additional 40,788 shares during the last quarter. Analysts Set New Price Targets Several equities analysts recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Xencor from $37.
00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. StockNews.
com lowered Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.38. Xencor Stock Performance XNCR stock opened at $8.
69 on Friday. The company has a quick ratio of 6.23, a current ratio of 6.
23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $612.
31 million, a PE ratio of -2.72 and a beta of 0.90.
The business has a 50 day moving average of $14.51 and a 200-day moving average of $19.69.
Xencor, Inc. has a 12-month low of $8.45 and a 12-month high of $27.
24. Xencor ( NASDAQ:XNCR – Get Free Report ) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.
62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19.
The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million.
Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%.
As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.
Xencor Profile ( Free Report ) Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Featured Stories Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Xencor, Inc. ( NASDAQ:XNCR – Free Report ). Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.
com's FREE daily email newsletter ..
